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INTRODUCTION
Chronic bladder pain syndromes such as interstitial cystitis/bladder pain syndrome (IC/BPS) and
chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affect patients with generalized pelvic pain,
frequent urination, and nocturia in the absence of infection1,2. The etiologies of these syndromes are
unknown, thus the sufficiency of current therapy methods is hindered3. In order to learn more about
chronic bladder pain and develop effective treatments, animal models are designed to recapitulate bladder
pain symptoms in rodents4. In our studies, we focused on a specific model in which male and female mice
are repeatedly administered a low dose injection of a chemotherapeutic agent, cyclophosphamide
(CYP)3,5. After cyclophosphamide is injected into the abdominal cavity it metabolizes into the bladder
irritant, acrolein, and induces bladder nociception (i.e. pain)6.
In addition to bladder nociception, repeated cyclophosphamide injections have been shown to
increase bladder weight, decrease body weight, and increase bladder tissue thickness3,7. We do not know,
however, how long these effects persist. It is important to fully understand the time parameters of this
model so that we can establish one that is more representative of chronic bladder pain syndromes.
Therefore we explored the chronicity of repeated cyclophosphamide injections in both male and female
mice after injecting them with 100 mg/kg of cyclophosphamide every other day for five days. Throughout
our experiments we measured the animals’ referred abdominal hypersensitivity levels, body, bladder, and
prostate weights, and tissue thicknesses. We hypothesized that the effects of this model would last for at
least seven days10.

METHODS
Cyclophosphamide Administration
IC/BPS-like symptoms were induced by administering 100 mg/kg CYP (dissolved in 0.9% saline)
intraperitoneally on days 1, 3, and 5. CYP was purchased from Sigma. Control animals received a 0.9%
saline intraperitoneal injection on days 1, 3, and 5. Subsequent behavioral testing/tissue collection was
completed on days 6 and 13.

Abdominal Hypersensitivity Test
Referred bladder pain was measured by assessing abdominal mechanical hypersensitivity. Two
days prior to testing the mice were anesthetized with isoflurane and their abdominal regions were shaved
to prevent hair from interfering with testing. On the days of testing, the animals habituated in plexiglass
boxes that were separated with plastic dividers for approximately 90 minutes, and then for another 30
minutes with the experimenter in the room. Calibrated von Frey filaments were applied to the shaved
abdomen in a graded fashion in order to determine the pressure at which the animal withdrew its abdomen
50% of the time (Figure 1.). The baseline 50% withdrawal threshold was determined on day 0 in both
male and female mice (genders were tested on different days) using the previously published up/down
method9. The abdominal region was probed approximately 0.5cm away from the urethra on both the left
and right side, and two trials were performed on each side. This process was repeated one and seven days
following the final injection of cyclophosphamide (days 6 and 13).

Figure 1. Mechanical hypersensitivity test set-up. Mechanical hypersensitivity tests were
performed using von Frey filaments. The mice were kept in a cage with a wire floor to allow
abdominal probing.

Body, Bladder, and Prostate Weights
The body weight of each animal was measured before von Frey testing on day 0, 6, and 13. On
day 13 the animals were injected with Euthasol and were sacrificed. Their bladders were immediately
harvested and weighed. Additionally, the males’ prostates were harvested and weighed. The bladders and
prostates were then fixed overnight in paraformaldehyde, cryopreserved in 20% sucrose for
approximately two days, frozen in OCT, and stored at -80°C.

Bladder Histology
Bladder histology was performed to determine whether the repeated cyclophosphamide injections
resulted in a change in bladder tissue morphology. To assess the affects, the bladders were cut into 30μm
sections, mounted onto glass slides, and stained using an optimized hematoxylin and eosin staining
procedure. In this procedure, the slides were stained with hematoxylin for four minutes, rinsed under tap
water for five minutes, incubated in acid alcohol (95% ethanol, 10% acetic acid) for one minute, rinsed
under tap water for one minute, and stained with eosin for five seconds. The slides were then dipped into
deionized water to rinse off excess eosin, and finally they were dehydrated using 50%, 75%, 95%, and
100% ethanol.
A light microscope was used to take pictures of the bladder sections at 40x magnification so that
the thickness of the various tissue layers could be measured using imaging analysis. Four bladders from
each treatment group and three sections from each bladder were used to acquire an average thickness of
each tissue layer. Image J software was used to measure the thickness of the urothelium, submucosa, and
muscularis layers in pixels (Figure 2.). The measurements were converted to micrometers.

Figure 2. Bladder Tissue Anatomy. Hematoxylin and eosin staining exposed the various tissue layers
within the bladder. The white region is the hollow bladder lumen. The three main layers of the bladder
include (listed from deep to superficial) the urothelium, submucosa, and the muscularis.

RESULTS
Repeated CYP Injections Induce Referred Abdominal Hypersensitivity in Females for at Least
Seven Days.
In both male and female mice, abdominal von Frey tests were performed on day 0, 6, and 13 to
assess the degree of referred bladder pain. CYP-treated females exhibited significant increases in referred
bladder pain (i.e. decreases in 50% withdrawal thresholds) when compared to saline-treated females
(Figure 3; Two-way ANOVA, main effect of treatment p<0.0001, main effect of interaction p=0.0202).
Bonferroni’s posttest revealed that the withdrawal threshold on day 6 was significantly lower in the CYPtreated females than in the saline-treated females (p<0.001). Thus, this data suggests that repeated CYP
injections induce referred abdominal hypersensitivity in female mice for at least seven days.
CYP treatment failed to induce the same increases in referred bladder pain in male mice (Figure
4.; Two-way ANOVA, effect of treatment p=0.1558) Therefore, in this experiment repeated CYP
injections did not induce referred abdominal hypersensitivity.
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Figure 3. Repeated CYP injections induce referred abdominal hypersensitivity in females for at least
seven days. Female mice underwent abdominal von Frey tests on days 0, 6, and 13. A two-way ANOVA
showed a main effect of treatment (p<0.0001) and interaction (p=0.0202). Bonferroni’s posttest showed a
significantly lower 50% withdrawal threshold in CYP-treated mice compared to saline-treated mice on day 6
(p<0.001). A similar trend was seen on day 13 (without significance) (day 0 and 6 n=12, day 13 n=6).
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Figure 4. Repeated CYP injections did not induce referred abdominal hypersensitivity in male mice.
Male mice underwent abdominal von Frey on days 0, 6, and 13. A two-way ANOVA showed that there
was no change in 50% withdrawal threshold in either group (p=0.1558) Bonferroni’s posttest revealed that
there was no statistical difference between the 50% withdrawal thresholds in the CYP and saline-treated
mice on days 0, 6, and 13 (day 0, 6, and 13 n=12).

Repeated CYP Injections Cause the Changes in Body, Bladder, and Prostate Weights to Last for at
Least Seven Days in Both Genders
The animals’ body weights were measured on day 0, 6, and 13. In both genders, CYP treatment
significantly decreased body weight 6 and 13 days following the start of treatment (Figure 5.; Females:

Two-way ANOVA, effect of treatment p<0.0001, Bonferroni’s posttest on day 6 and 13 p<0.001; Males:
Two-way ANOVA, effect of treatment p<0.0001, Bonferroni’s posttest on day 6 and 13 p<0.001). On day
13 the bladders were harvested and weighed. The CYP-treated females had significantly larger bladder
weights than the saline-treated females (Figure 6.; unpaired t-test p=0.0007), while the males did not
show changes in bladder weight (data not shown). The males’ prostates were also collected and weighed
on day 13, and the CYP-treated males had significantly lower prostate weights than those of the salinetreated males (Figure 7.; unpaired t-test p=0.0304). This data suggests that the changes observed in body,
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bladder, and prostate weights are maintained in both male and female mice for at least seven days.
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Figure 5. Decreases in body weights were maintained for at least seven days. The male and female body
weights were measured on days 6 and 13. Females: A two-way ANOVA showed an effect of treatment
(p<0.0001). Bonferroni’s posttest showed that the CYP-treated females had significantly larger decreases in
body weight than the saline-treated females on day 6 and 13 (p<0.0001). Males: A two-way ANOVA showed
an effect of treatment (p<0.0001). Bonferroni’s posttest showed that CYP-treated males had significantly
larger decreases in body weight than saline-treated males on day 6 and 13 (p<0.0001) (day 6 n=12, day 13
male n=12, day 13 female n=6).
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Figure 6. Female bladder weight increases were maintained for at least seven days. Female bladders were
harvested and weighed on day 13. An unpaired t-test showed that the CYP-treated bladders had significantly
larger weights than the saline-treated bladders (p = 0.0007) (n=6).

Prostate Weight (% Body Weight)

Prostate Weight

*

0.25
0.20
0.15
0.10
0.05
0.00

Saline

CYP

Figure 7. Decreases in prostate weights were maintained for at least seven days. The male prostates
were harvested and weighed on day 13. An unpaired t-test revealed that CYP-treated males had prostates
with significantly lower weights compared to the saline-treated males (p = 0.0304).

Repeated CYP Injections Cause Increases in Bladder Tissue Thickness that Lasts for at Least
Seven Days
After the female bladders were harvested and preserved, they were sectioned, stained, and
analyzed to explore changes in bladder tissue thicknesses. CYP treatment increased urothelium thickness
(Figure 8.; One-way ANOVA p=0.0047, Bonferroni’s posttest on day 6 p<0.01, on day 13 p<0.05),
submucosa thickness (Figure 8.; One-way ANOVA p=0.0004, Bonferroni’s posttest on day 13 p<0.0001),
and muscularis thickness (Figure 8.; One-way ANOVA p=0.0013, Bonferroni’s posttest on day 6 p<0.01,
on day 13 p<0.05) for at least seven days following the start of drug treatment. These procedures have not

yet been completed in the male mice bladders, but they suggest that repeated low-dose administration of
CYP induces long lasting changes in bladder morphology.
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Figure 8. Repeated CYP injections induced an increase in bladder tissue thickness for at least seven
days in females. Female bladders were cut into 30μm sections and stained. The thickness of the bladder
tissue layers (the urothelium, submucosa, and muscularis) was measured. A one-way ANOVA revealed
that each layer increased in thickness for at least seven days following CYP treatment (urothelium
p=0.0047; submucosa p=0.0004; muscularis p=0.0013) Bonferroni’s posttests showed that these tissue
layers in CYP-treated mice were significantly thicker on both day 6 and 13 (p<0.05, p<0.01, p<0.0001).
DISCUSSION
In these experiments we investigated how long the effects of repeated CYP injections persist in
both male and female mice. We found that the effects, such as increases in referred abdominal
hypersensitivity, changes in body, bladder, and prostate weights, and increases in bladder tissue thickness
last in both genders for at least seven days. In the male mice, however, we did not see an effect of
repeated CYP injections in the context of referred abdominal hypersensitivity, even though there was a
decrease in body and prostate weight. One potential explanation for this inconsistency is that the male

mice displayed baseline withdrawal thresholds that were higher than the von Frey filaments used in the
experiments. To further explain the effects that repeated CYP injections have on referred abdominal
hypersensitivity in male mice, the procedure described above will be repeated. If similar results are
attained, the extent of male baseline withdrawal thresholds will be explored to determine if larger
filaments must be used.

FUTURE DIRECTIONS
We plan to fully characterize the time parameters of this model and identify the latest time point
at which it has an effect in male and female mice. Additionally, using our understandings of the model’s
timeline, we plan to develop a model of chronic bladder pain in which the animals are exposed to earlylife stress before they receive CYP injections, as many bladder pain patients report stressful childhoods8.
It is hopeful that through these efforts we will develop a model of chronic bladder pain that accurately
represents clinical symptomology, thus enabling researchers to explore the etiologies of bladder pain
syndromes.
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